This study examines the role of the Bowman-Birk protease inhibitor (BBI) in enhancing the oral bioavailability and cancer-preventive activity of lunasin, a soy-derived peptide known for its epigenetic modulation properties. Lunasin binds to deacetylated histones and inhibits histone acetylation, thereby regulating gene expression involved in tumorigenesis. However, its effectiveness is
